Table 1 Characteristics of women referred to an image-guided breast biopsy, by biopsy diagnosis
Characteristics | All women (N = 195) | Women with proliferative diagnosis1 (N = 141) | Women with non-proliferative diagnosis2 (N = 54) | P-value§ |
|---|---|---|---|---|
Age (years), mean (SD) | 50.6 (6.4) | 51.4 (6.4) | 48.5 (6.2) | 0.005 |
Age (years), n (%) | Â | Â | Â | 0.040 |
  < 45 | 38 (19.5) | 21 (14.9) | 17 (31.5) |  |
 45–49 | 51 (26.2) | 36 (25.5) | 15 (27.8) |  |
 50–54 | 53 (27.2) | 41 (29.1) | 12 (22.2) |  |
  ≥ 55 | 53 (27.2) | 43 (30.5) | 10 (18.5) |  |
Race/Ethnicity, n (%) | Â | Â | Â | 1.00 |
 White, non-Hispanic | 184 (94.4) | * | * |  |
 Non-White | 11 (5.6) | * | * |  |
Education, n (%) | Â | Â | Â | 0.970 |
 High school or less | 29 (14.9) | 21 (14.9) | 8 (14.8) |  |
 Some college | 34 (17.4) | 24 (17.0) | 10 (18.5) |  |
 College graduate or more | 132 (67.7) | 96 (68.1) | 36 (66.7) |  |
Age at menarche (years), n (%) | Â | Â | Â | 0.476 |
  ≤ 12 | 75 (39.1) | 57 (40.7) | 18 (34.6) |  |
 13 | 68 (35.4) | 46 (32.9) | 22 (42.3) |  |
  ≥ 14 | 49 (25.5) | 37 (26.4) | 12 (23.1) |  |
Parity, n (%) | Â | Â | Â | 0.280 |
 Nulliparous | 49 (25.1) | 32 (22.7) | 17 (31.5) |  |
 Parous | 146 (74.9) | 109 (77.3) | 37 (68.5) |  |
Age at first birth¶ (years), n (%) |  |  |  | 0.639 |
  < 30 | 105 (71.9) | 80 (73.4) | 25 (67.6) |  |
  ≥ 30 | 41 (28.1) | 29 (26.6) | 12 (32.4) |  |
Menopausal status, n (%) | Â | Â | Â | 0.103 |
 Premenopausal | 125 (64.1) | 85 (60.3) | 40 (74.1) |  |
 Postmenopausal | 70 (35.9) | 56 (39.7) | 14 (25.9) |  |
Age at menopause (years), n (%) | Â | Â | Â | 0.873 |
  < 45 | 12 (19.7) | 9 (18.8) | 3 (23.1) |  |
 45–49 | 17 (27.9) | 13 (27.1) | 4 (30.8) |  |
  ≥ 50 | 32 (52.5) | 26 (54.2) | 6 (46.2) |  |
Menopausal hormone therapy use‡, n (%) |  |  |  | 0.039 |
 Never | 37 (52.9) | 26 (46.4) | 11 (78.6) |  |
 Ever | 33 (47.1) | 30 (53.6) | 3 (21.4) |  |
Body mass index (kg/m2), mean (SD) | 25.9 (5.4) | 25.8 (5.5) | 25.9 (5.2) | 0.649 |
Body mass index (kg/m2), n (%) | Â | Â | Â | 0.158 |
  < 25.0 | 103 (52.8) | 78 (55.3) | 25 (46.3) |  |
 25.0–29.9 | 53 (27.2) | 33 (23.4) | 20 (37.0) |  |
  ≥ 30 | 39 (20.0) | 30 (21.3) | 9 (16.7) |  |
First degree family history of breast cancer, n (%) | Â | Â | Â | 0.891 |
 No | 144 (73.8) | 105 (74.5) | 39 (72.2) |  |
 Yes | 51 (26.2) | 36 (25.5) | 15 (27.8) |  |
Primary pathologic diagnosis, n (%) | Â | Â | Â | -- |
 Benign | 42 (21.5) | -- | 42 (77.8) |  |
 Other discrete non-proliferative diagnosis | 12 (6.2) | -- | 12 (22.2) |  |
 Hyperplasia | 110 (56.4) | 110 (78.0) | -- |  |
 In-situ carcinoma | 22 (11.3) | 22 (15.6) | -- |  |
 Invasive carcinoma | 9 (4.6) | 9 (6.4) | -- |  |
Mammographic density measure¥, mean (SD) |  |  |  |  |
 % density (volume) | 41.4 (21.5) | 41.6 (20.9) | 41.1 (23.0) | 0.692 |
 Dense volume (cm3) | 193.5 (93.8) | 195.1 (99.7) | 189.2 (76.7) | 0.992 |
 Total breast volume (cm3) | 603.8 (389.8) | 607.8 (407.0) | 593.3 (344.1) | 0.776 |
 % density (area) | 30.6 (21.0) | 30.0 (20.9) | 32.1 (21.5) | 0.539 |
 Dense area (cm2) | 35.9 (26.7) | 35.3 (26.0) | 37.6 (28.8) | 0.886 |
 Total breast area (cm2) | 141.2 (69.3) | 143.9 (72.7) | 134.2 (59.3) | 0.655 |
Relative leukocyte telomere length, mean (SD) | Â | Â | Â | Â |
 Overall | 1.5 (0.8) | 1.6 (0.9) | 1.2 (0.6) | 0.002 |
 Benign | 1.2 (0.5) | -- | 1.2 (0.5) |  |
 Other discrete non-proliferative diagnosis | 1.3 (1.0) | -- | 1.3 (1.0) |  |
 Hyperplasia | 1.6 (0.8) | 1.6 (0.8) | -- |  |
 In-situ carcinoma | 1.8 (1.2) | 1.8 (1.2) | -- |  |
 Invasive carcinoma | 1.4 (0.7) | 1.4 (0.7) | -- |  |